Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8205634 | 0.88 | SLC10A2 (0.64) | SLC10A2 | |
| SCHEMBL8201524 | 0.82 | SLC10A2 (0.63) | SLC10A2 | |
| SCHEMBL6823538 | 0.81 | SLC10A2 (0.58) | SLC10A2 | |
| SCHEMBL6827627 | 0.81 | SLC10A2 (0.58) | SLC10A2 | |
| SCHEMBL6201735 | 0.81 | SLC10A2 (0.58) | SLC10A2 | |
| SCHEMBL6827130 | 0.80 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL6827584 | 0.80 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL6198552 | 0.80 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL8566139 | 0.77 | SLC10A2 (0.62) | SLC10A2 | |
| SCHEMBL8201532 | 0.77 | SLC10A2 (0.64) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0971744-A2 | COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998040375-A2 | COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-09-17 | — | — | WO | disclosed |
| WO-1997033882-A9 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | — | 1998-02-26 | — | — | WO | disclosed |